Kindred Bio

KIN NASDAQ
6.12
-0.21
-3.32%
盘后: 6.12 0 0.00% 16:51 07/23 EDT
开盘
6.33
昨收
6.33
最高
6.35
最低
5.96
成交量
21.92万
成交均量(3M)
17.15万
52周最高
15.75
52周最低
5.96
换手率
0.56%
市值
2.39亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Kindred Bio KIN股票价格,Kindred Bio股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
展开 >

最近浏览

名称
价格
涨跌幅